Displaying drugs 2326 - 2350 of 15210 in total
Synthetic Conjugated Estrogens, A
Synthetic conjugated estrogens A are composed of a blend of the following nine synthetic estrogenic substances: estrone sulfate, sodium equilin sulfate, sodium 17α-dihydroequilin sulfate, sodium 17α-estradiol sulfate, sodium 17β dihydroequilin sulfate, sodium 17α-dihydroequilenin sulfate, sodium 17β-dihydroequilenin sulfate, sodium equilenin sulfate, and sodium 17β-estradiol sulfate. This blend of nine estrogen derivatives...
Approved
Matched Description: … dryness, and vulvovaginal atrophy. ... estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control ... after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Synthetic Conjugated Estrogens, B
Synthetic conjugated estrogens, B tablets contain a blend of ten synthetic estrogenic substances. The estrogenic substances are: sodium estrone sulfate, sodium equilin sulfate, sodium 17α-dihydroequilin sulfate, sodium 17α-estradiol sulfate, sodium 17β dihydroequilin sulfate, sodium 17α-dihydroequilenin sulfate, sodium 17β-dihydroequilenin sulfate, sodium equilenin sulfate, sodium 17β-estradiol sulfate, and sodium Δ8,9-dehydroestrone sulfate. This...
Approved
Matched Description: … dryness, and vulvovaginal atrophy. ... estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control ... after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Pexidartinib
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial...
Approved
Investigational
Matched Description: … tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue. ... Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August ... [A182243] Pexidartinib is available in oral formulations and it is commonly marketed as Turalio. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Roflumilast
Roflumilast is a highly selective phosphodiesterase-4 (PDE4) inhibitor. PDE4 is a major cyclic-3',5′-adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme expressed on nearly all immune and pro-inflammatory cells, in addition to structural cells like those of the smooth muscle or epithelium. The resultant increase in intracellular cAMP induced by roflumilast's inhibition of PDE4...
Approved
Matched Description: … [L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018. ... adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme [L37564] expressed on nearly all immune and ... The cream formulation was first approved by the FDA in July 2022 [L42580] and by Health Canada in April …
Belatacept
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Investigational
Matched Description: … domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and ... Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Axicabtagene ciloleucel
Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express...
Approved
Matched Description: … It is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular ... kill cancer cells, and are infused back into the patient. ... collected from the patient, they are genetically engineered to express anti-CD19 CARs that recognize and …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …
Besilesomab
Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis [FDA Label]. Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like...
Approved
Matched Description: … Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and ... various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the Netherlands, and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Fluoroestradiol F-18
Fluoroestradiol F-18 is an imaging agent used with positron emission tomography (PET) to detect estrogen receptor-positive breast cancer lesions. The ability to image ER-positive tumors in vivo is advantageous in that, while helping to visualize tumor progression/regression, it may also be used to assess for heterogeneity in ER expression across...
Approved
Matched Description: … PETNET Solutions, Inc. and Zionexa USA under the brand name Cerianna. ... [A203912]
Fluoroestradiol F-18 was first granted FDA approval in May 2020, and will be developed by …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Bisoctrizole
Bisoctrizole, or methylene bis-benzotriazolyl tetramethylbutylphenol, is a broad-spectrum organic UV filter that is marketed as Tinosorb M . It is a benzotriazole-based organic compound that absorbs, reflects, and scatters both UV-A and UV-B rays. Bisoctrizole is not approved by the FDA, but is approved in the EU and other parts...
Approved
Matched Description: … It is a benzotriazole-based organic compound that absorbs, reflects, and scatters both UV-A and UV-B ... Bisoctrizole is not approved by the FDA, but is approved in the EU and other parts of the world as a ... UV-filter in sunscreens, day care products and skin lightening products at a maximum concentration of …
Alefacept
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Approved
Investigational
Withdrawn
Matched Description: … CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Caplacizumab
Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy...
Approved
Investigational
Matched Description: … Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and ... approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs …
Ambroxol
Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the...
Approved
Investigational
Matched Description: … in providing protection against infection and irritating agents. ... It stimulates synthesis and release of surfactant by type II pneumocytes. ... The substance is a mucoactive drug with several properties including secretolytic and secretomotoric …
Matched Categories: … Cough and Cold Preparations ... clenbuterol and ambroxol …
Matched Categories: … Cough and Cold Preparations ... clenbuterol and ambroxol …
Segesterone acetate
Segesterone acetate is a steroidal progestin or synthetic progesterone and a 19-norprogesterone derivative with no CH3 group radical in position 6 . In animal studies, segesterone acetate was shown to be one of the most potent progestins . It mediates progestational activity 100 times higher than that of progesterone ....
Approved
Experimental
Investigational
Matched Description: … low-birth-weight infants, and physical and mental health risks [L4246]. ... It is commonly sold under the brand names Nestorone and Elcometrine and serves as an active component ... Food and Drug Administration (FDA) as the first and only contraceptive that provides an entire year of …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Ritlecitinib
Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further...
Approved
Investigational
Matched Description: … 12 years and older. ... This makes ritlecitinib a highly selective and irreversible JAK3 inhibitor. ... [L48181] Ritlecitinib is administered orally and is the first member of its class. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Vespula squamosa venom protein
Vespula squamosa venom protein is an extract of Vespula squamosa venom. Vespula squamosa venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Sotatercept
Sotatercept is an activin signalling inhibitor. It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain. On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension...
Approved
Investigational
Matched Description: … [L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Efbemalenograstim alfa
Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration.[L48852,A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim...
Approved
Matched Description: … GC-627-05 in the US and Europe respectively. ... thus reducing the severity and duration of neutropenia. ... A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Protamine sulfate
Since it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps the only viable option for reversing the anticoagulant effect of heparin use for over 77 years [A174778,...
Approved
Matched Description: … kidney tissue damage, and anaphylactic reaction, amongst others [A174778, L5371]. ... reversal predominantly via the formation of an inactive complex between the anionic nature of heparin and ... potential range in reversing all parenteral anticoagulants are sometimes considered high and limited …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Inotuzumab ozogamicin
Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects. Inotuzumab ozogamicin was first...
Approved
Investigational
Matched Description: … [A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Oteseconazole
Oteseconazole is an azole metalloenzyme inhibitor that targets fungal CYP51. CYP51, also known as 14α demethylase, participates in the formation of ergosterol, a compound that plays a vital role in the integrity of cell membranes.[L41635,A247020] By binding and inhibiting CYP51, oteseconazole is active against most microorganisms associated with recurrent vulvovaginal...
Approved
Investigational
Matched Description: … [L41635,A247020] By binding and inhibiting CYP51, oteseconazole is active against most microorganisms ... Candida glabrata_, _Candida krusei_, _Candida parapsilosis_, _Candida tropicalis_, _Candida lusitaniae_ and ... L41635]
Unlike previous-generation azole antifungals, oteseconazole has a high selectivity for CYP51 and …
Matched Categories: … Triazole and tetrazole derivatives …
Matched Categories: … Triazole and tetrazole derivatives …
Belumosudil
Belumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated for the treatment of pulmonary arterial hypertension. It is an inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK), with significantly more selectivity for ROCK2 as compared to ROCK1 (IC50 100 nM vs. 3 μM, respectively). In...
Approved
Investigational
Matched Description: … Belumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated ... HSCT), belumosudil helps to resolve immune dysregulation by shifting the balance between Th17 cells and ... July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Amsacrine
Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression...
Approved
Investigational
Matched Description: … It produces consistent but acceptable myelosuppression and cardiotoxic effects. ... It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in …
Matched Categories: … Indicators and Reagents ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Indicators and Reagents ... Antineoplastic and Immunomodulating Agents …
Keyhole limpet hemocyanin
Keyhole limpet hemocyanin is an immune modulator, given as a vaccine to help the body respond to cancer. A natural protein isolated from the marine mollusc keyhole limpet. Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such...
Approved
Investigational
Matched Description: … hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Displaying drugs 2326 - 2350 of 15210 in total